Report Company Directory
- Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division by GlobeNewsWire
- Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance by GlobeNewsWire
- Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess by GlobeNewsWire
- CORRECTION - Elevai Labs Inc. by GlobeNewsWire
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update by GlobeNewsWire
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange by GlobeNewsWire
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity by GlobeNewsWire
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity by GlobeNewsWire
- Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock by GlobeNewsWire
- REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations by GlobeNewsWire